Feedback
Settings

Settings

Goto Application

1. WO2005087253 - INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES

PermaLink
Publication Number WO/2005/087253
Publication Date 22.09.2005
International Application No. PCT/GB2005/050031
International Filing Date 07.03.2005
IPC
A61K 9/12 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
10Dispersions; Emulsions
12Aerosols; Foams
A61K 31/57 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
A61K 38/21 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons
CPC
A61K 31/56
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
A61K 31/7088
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
A61K 38/21
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons ; [IFN]
A61K 38/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
19Cytokines; Lymphokines; Interferons
21Interferons ; [IFN]
215IFN-beta
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61M 16/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY
16Devices for influencing the respiratory system of patients by gas treatment, e.g. mouth-to-mouth respiration; Tracheal tubes
10Preparation of respiratory gases or vapours
14by mixing different fluids, one of them being in a liquid phase
Applicants
  • UNIVERSITY OF SOUTHAMPTON [GB]/[GB] (AllExceptUS)
  • DAVIES, Donna, Elizabeth [GB]/[GB] (UsOnly)
  • WARK, Peter, Alexander, Blanch [AU]/[GB] (UsOnly)
  • HOLGATE, Stephen [GB]/[GB] (UsOnly)
  • JOHNSTON, Sebastian, L. [GB]/[GB] (UsOnly)
Inventors
  • DAVIES, Donna, Elizabeth
  • WARK, Peter, Alexander, Blanch
  • HOLGATE, Stephen
  • JOHNSTON, Sebastian, L.
Agents
  • IRVINE, Jonquil, Claire
Priority Data
0405634.712.03.2004GB
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) INTERFERON-BETA FOR ANTI-VIRUS THERAPY FOR RESPIRATORY DISEASES
(FR) THERAPIE ANTIVIRUS POUR LE TRAITEMENT DE MALADIES RESPIRATOIRES
Abstract
(EN)
The present invention provides the use of IFN-&bgr;, an agent that increases the expression of IFN-&bgr;, or a polynucleotide which is capable of expressing IFN-&bgr; or said agent for the manufacture of a medicament for the treatment of rhinovirus-induced exacerbation of a respiratory disease selected from asthma and chronic obstructive pulmonary disease, wherein said treatment is by airway delivery of said medicament, e.g. by use of an aerosol nebuliser.
(FR)
L'invention concerne l'utilisation de IFN-$g(b), d'un agent qui augmente l'expression de IFN-$g(b), ou d'un polynucléotide capable d'exprimer IFN-$g(b) ou dudit agent pour la fabrication d'un médicament destiné au traitement de l'exacerbation induite par le rhinovirus d'une maladie respiratoire choisie parmi l'asthme et la bronchopneumopathie chronique obstructive, ledit traitement s'opérant par administration dudit médicament par voie aérienne, par exemple par l'utilisation d'un nébuliseur aérosol.
Also published as
CA2558212
DK1734987
EP1734987
EP2206512
JP2007528890
US11517763
Other related publications
CA2787978
ES2343732
JP2011144201
PT1734987
US20070134763
US20090257980
US20130209399
Latest bibliographic data on file with the International Bureau
# -